VIRVir Biotechnology, Inc.

Nasdaq vir.bio


$ 8.46 $ 0.09 (1.08 %)    

Tuesday, 30-Apr-2024 15:59:59 EDT
QQQ $ 423.38 $ -8.16 (-1.89 %)
DIA $ 377.96 $ -5.67 (-1.48 %)
SPY $ 501.59 $ -8.08 (-1.58 %)
TLT $ 88.19 $ -0.76 (-0.85 %)
GLD $ 211.99 $ -4.31 (-1.99 %)
$ 8.46
$ 8.30
$ 0.00 x 0
$ 0.00 x 0
$ 8.23 - $ 8.48
$ 7.61 - $ 27.48
1,063,995
na
1.13B
$ -0.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-26-2024 12-31-2023 10-K
2 11-03-2023 09-30-2023 10-Q
3 08-04-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 02-28-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 02-25-2021 12-31-2020 10-K
14 11-10-2020 09-30-2020 10-Q
15 08-11-2020 06-30-2020 10-Q
16 05-12-2020 03-31-2020 10-Q
17 03-26-2020 12-31-2019 10-K
18 11-19-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 on-april-15-2024-sung-lee-executive-vice-president-and-chief-financial-officer-of-vir-biotechnology-informed-the-company-that-he-will-be-stepping-down-from-his-role-effective-may-3-2024-to-pursue-another-career-opportunity-co-has-initiated-a-search-for-his-successor

On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the "Company&...

 hc-wainwright--co-reiterates-buy-on-vir-biotechnology-maintains-110-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...

 vir-biotechnology-completes-enrollment-of-phase-2-chronic-hepatitis-delta-solstice-trial

– Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter –– Approximately 50% of par...

 why-mercadolibre-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter fin...

 carvana-posts-q4-results-joins-legalzoomcom-comfort-systems-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday.

 vir-biotechnology-q4-2023-gaap-eps-086-beats-100-estimate-sales-1679m-beat-1215m-estimate

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(1....

 earnings-scheduled-for-february-22-2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

 hc-wainwright--co-maintains-buy-on-vir-biotechnology-raises-price-target-to-110

HC Wainwright & Co. analyst Patrick Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price ta...

 jp-morgan-downgrades-vir-biotechnology-to-neutral-lowers-price-target-to-9

JP Morgan analyst Eric Joseph downgrades Vir Biotechnology (NASDAQ:VIR) from Overweight to Neutral and lowers the price targ...

 covax-global-initiative-for-covid-19-vaccines-comes-to-an-end-amid-shift-to-regular-programs

COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December ...

 vir-biotechnology-to-present-late-breaking-data-from-its-ongoing-phase-2-chronic-hepatitis-b-and-delta-trials-at-aaslds-the-liver-meeting-2023

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the...

 vir-biotechnology-inc-files-for-mixed-shelf-sales-agreement-prospectus-covers-offering-of-up-to-300m-of-common-stock-that-may-be-issued-and-sold-from-time-to-time

- SEC Filing

 needham-maintains-buy-on-vir-biotechnology-lowers-price-target-to-15

Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and lowers the price target from $22 to ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION